In a report released today, Matthew Harrison from Morgan Stanley maintained a Buy rating on Argenx Se (ARGX – Research Report), with a price target of $321.00. The company’s shares closed last Monday at $274.65.
According to TipRanks.com, Harrison is a 5-star analyst with an average return of 16.8% and a 58.6% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Freeline Therapeutics Holdings, and BioMarin Pharmaceutical.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Argenx Se with a $334.60 average price target.
The company has a one-year high of $382.15 and a one-year low of $139.78. Currently, Argenx Se has an average volume of 208.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.